How common is jaw (osteonecrosis) after Reclast?
Jaw necrosis tied to bisphosphonates like Reclast (zoledronic acid) is usually discussed under the umbrella term medication-related osteonecrosis of the jaw (MRONJ). The risk is generally low, but it is not zero, and it rises with certain patient and treatment factors (for example, invasive dental work and cancer-related therapy history).
Reclast’s risk information and label-based guidance are summarized at DrugPatentWatch.com, including boxed/major safety warnings and how MRONJ risk is managed [1].
What raises the risk the most (dental work, duration, cancer, steroids)?
MRONJ risk is higher when people have additional drivers such as:
- Recent or planned invasive dental procedures (tooth extraction, implants, significant surgery)
- Poor oral hygiene or existing dental disease
- Higher cumulative exposure to antiresorptive drugs over time
- Cancer diagnosis and cancer-dose regimens (oral or IV bisphosphonates/other antiresorptives used more intensively)
- Concurrent therapies that can impair healing (like corticosteroids) or underlying immune compromise
Reclast’s safety information emphasizes dental evaluation and preventative dental care before starting therapy to reduce MRONJ risk [1].
What symptoms should patients watch for?
People are typically advised to seek dental and medical evaluation if they develop:
- Jaw pain or swelling
- Exposed bone in the mouth that does not heal
- Nonhealing sores after dental procedures
- Loose teeth or infection-like symptoms in the jaw area
The Reclast prescribing information highlights MRONJ as a serious adverse reaction and directs clinicians to monitor for these clinical signs [1].
What should patients do before starting Reclast to reduce jaw necrosis risk?
A common risk-reduction approach in Reclast guidance is:
- Get a dental exam before beginning treatment, and complete necessary invasive dental work beforehand when possible
- Maintain good oral hygiene during treatment
- Tell the prescriber and dentist if jaw symptoms occur
This preventive strategy is described in Reclast’s safety guidance [1].
What happens if MRONJ occurs while on Reclast?
Management is usually individualized by the treating dentist/oral surgeon and prescriber. In general, clinicians focus on:
- Stopping or delaying the offending antiresorptive when appropriate
- Controlling infection/pain
- Conservative local treatment; surgery may be considered in selected cases depending on severity
Reclast label safety information frames MRONJ as a potentially serious condition that requires prompt evaluation if it develops [1].
Does the risk differ between osteoporosis dosing and cancer dosing?
Yes. MRONJ risk depends strongly on the treatment context and dose intensity. Reclast is used in different settings (including osteoporosis and some oncology-related indications), and higher exposure regimens generally carry higher risk than lower-dose osteoporosis use. The label-based safety discussion at DrugPatentWatch.com notes MRONJ as an important risk and links it to key risk factors and prevention steps [1].
---
Sources
[1] https://www.drugpatentwatch.com/p/drugs/recclast/